WHO reaches ivermectin recommendation without a vote

WHO reaches ivermectin recommendation without a vote

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.

By Peter Yim

WHO updated “Therapeutics and COVID-19” on March 31, 2021 to include a recommendation on ivermectin. The recommendation was:

“We recommend not to use ivermectin in patients with COVID-19 except in the context of a clinical trial.”

The recommendation was made by the Guideline Development Group; 63 members consisting of “content experts, clinicians, patients, ethicists and methodologists”.

WHO explained that a vote on the recommendation was not necessary:

“While a priori voting rules informed procedures if the panel failed to reach consensus, these procedures proved unnecessary for this recommendation.”

Two questions:

  1. Was there an “a priori” system in place for deciding when and how to abandon the “a priori” voting rules?
  2. How was consensus determined?
  3. Is it too late to take a vote?

WHO explained how they reached their “transparent and trustworthy recommendations”. They need to understand that bypassing a vote on the recommendation is the opposite of transparent and trustworthy.


  1. Did you expect anything different? Any inexpensive, off-patent treatment, no matter how effective, must be beaten down and blackballed. Patient health and survival does not matter; massive profits for the research companies and the Big Pharm industry is the one and only goal. You’d have to be deaf, dumb, and blind not to accept this, after seeing it dozens of times over the past 16 months.